Business
Cannabics Pharmaceuticals Closes Agreement With Wize Pharma
Cannabics Pharmaceuticals Closes Agreement With Wize Pharma.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCannabics Pharmaceuticals Closes Agreement With Wize Pharma\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntaj{\nTEXT-ALIGN: JUSTIFY\n}\n\n\n\n\n\n\nCannabics Pharmaceuticals Closes Agreement With Wize Pharma\nCompanies to Found New Company to Research and Develop Cannabinoid Formulations to Treat Ophthalmic Disorders\nPR Newswire\nBETHESDA, Maryland and TEL AVIV, Israel, March 6, 2019\n\n\n\nBETHESDA, Maryland and TEL AVIV, Israel, March 6, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) a world leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has closed an agreement with Wize Pharma, Inc. (OTCQB: WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, and that has distribution rights of known medical formulae related to eye diseases, to form a equally owned joint venture (JV) which will focus on the research and development of cannabinoid based treatments for ophthalmic disorders.\n\n \n \n\n \nInitially announced in a press release on June 29, 2018, and then on February 7, 2019, the two companies have obtained an expert opinion which they believe identifies a potential route with the U.S. Food and Drug Administration for an ophthalmic therapy containing cannabinoids. Pursuant to the JV agreement signed on February 7, 2019, the successful completion of the above marks the initial closing of the agreement and the commencement of the JV, subject to the formation of the JV entity and the completion of a mutually agreeable business plan. \n\"We believe that the closing of this agreement emphasizes the potential embodied in cannabinoid-based therapies which can be used to treat ophthalmic disorders. The agreement supports our vision which is to bring cannabinoid-based therapies to modern medicine, which may be used as treatments for a wide variety of conditions,\" said Eyal Barad, Cannabics' CEO and Co-Founder.\n\"We are pleased to leverage our team and know-how as well as our lab and R&D license to support such joint venture...